Promomed's revenue for 9 months of 2025 amounted to ₽19 billion, an increase of 78% compared to last year. Revenue growth is 6 times higher than the growth rate of the pharmaceutical market, which amounted to 12.6%. Share of revenue from the sale of drugs in the endocrinological and oncological portfolios increased by 22 percentage points and amounted to 75%...

Promomed company has registered the first Russian analogue of Ozempika in the form of tablets. Semaltara will be available in three dosages: 3 mg, 7 mg and 14 mg. Company is already producing analogues of Ozempika in injectable form - Velgia and Quincenta.

Promomed has launched the first-in-class drug Amberwin® Pulmo with a unique mechanism of action and high efficacy in improving lung health in a wide range of diseases. It is a bioregulator from the class of short peptides, created on the company's own technology platform. Active ingredient of the drug is a synthetic peptide of six amino acids combined with a...

Biopharmaceutical company Promomed and the Vietnamese pharmaceutical corporation Vinafarm signed a memorandum of understanding. Document defines the terms of cooperation in such areas as the commercialization of medicines, the development of production technologies, research and synthesis of new molecules. Cooperation with Vinafarm will allow Promomed to exp...